We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-4.37%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$522M
AUM Growth
-$120M
Cap. Flow
-$60.3M
Cap. Flow %
-11.56%
Top 10 Hldgs %
58.05%
Holding
42
New
7
Increased
15
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$16.4M
2
KALV
KalVista Pharmaceuticals
KALV
+$15.6M
3
MRUS
Merus
MRUS
+$14.5M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$13.5M
5
VYGR icon
Voyager Therapeutics
VYGR
+$13.4M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$44.7M
2
APGE icon
Apogee Therapeutics
APGE
+$26.6M
3
JBIO
Jade Biosciences
JBIO
+$26.2M
4
ANAB icon
AnaptysBio
ANAB
+$22.2M
5
INSM icon
Insmed
INSM
+$20.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
URGN icon
1
UroGen Pharma
URGN
$1.86B
$48.8M 9.34%
2,906,259
+285,714
+11% +$4.06M
NGNE icon
2
Neurogene
NGNE
$656M
$36.5M 7%
1,004,291
– –
ABVX
3
Abivax
ABVX
$10.9B
$32.7M 6.26%
2,472,188
-16,295
-0.7% -$233K
MRUS
4
DELISTED
Merus
MRUS
$31M 5.93%
523,288
+300,000
+134% +$14.5M
PLRX icon
5
Pliant Therapeutics
PLRX
$64.4M
$28.3M 5.43%
2,636,864
+785,000
+42% +$10.1M
ACLX
6
DELISTED
Arcellx
ACLX
$27.2M 5.2%
492,000
+192,000
+64% +$10.4M
DVAX
7
DELISTED
Dynavax Technologies
DVAX
$26.7M 5.11%
2,374,000
+1,109,080
+88% +$12.9M
EOLS icon
8
Evolus
EOLS
$385M
$26.6M 5.1%
2,451,772
+1,772
+0.1% +$21.8K
CYTK icon
9
Cytokinetics
CYTK
$10.5B
$25.7M 4.92%
474,202
+272,000
+135% +$16.4M
DNTH icon
10
Dianthus Therapeutics
DNTH
$5.84B
$19.6M 3.76%
757,929
+132,929
+21% +$3.2M
INSM icon
11
Insmed
INSM
$21.4B
$16.8M 3.21%
250,000
-525,585
-68% -$20.4M
ZURA icon
12
Zura Bio
ZURA
$516M
$16.2M 3.11%
4,642,241
+1,884,501
+68% +$7.68M
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
$15.8M 3.02%
+1,338,568
New +$15.6M
IONS icon
14
Ionis Pharmaceuticals
IONS
$8.6B
$15.7M 3.01%
+330,000
New +$13.5M
CNTX icon
15
Context Therapeutics
CNTX
$55.1M
$14.9M 2.85%
+7,419,355
New +$12.8M
FOLD
16
DELISTED
Amicus Therapeutics
FOLD
$14.8M 2.84%
1,495,500
– –
OPTN
17
DELISTED
OptiNose
OPTN
$14.3M 2.73%
915,140
+329,385
+56% +$5.52M
ESPR
18
DELISTED
Esperion Therapeutics
ESPR
$12.9M 2.46%
5,791,594
-2,208,406
-28% -$5.2M
VYGR icon
19
Voyager Therapeutics
VYGR
$183M
$12.7M 2.43%
+1,601,527
New +$13.4M
OTLK icon
20
Outlook Therapeutics
OTLK
$183M
$12.6M 2.41%
1,701,510
+221,510
+15% +$1.78M
AUTL
21
Autolus Therapeutics
AUTL
$397M
$12M 2.29%
3,441,667
+2,275,000
+195% +$9.82M
JSPR icon
22
Jasper Therapeutics
JSPR
$21M
$9.13M 1.75%
402,015
-5,535
-1% -$133K
OLMA icon
23
Olema Pharmaceuticals
OLMA
$1B
$8.62M 1.65%
+796,880
New +$8.64M
TERN
24
DELISTED
Terns Pharmaceuticals
TERN
$7.83M 1.5%
1,149,406
-160,569
-12% -$973K
VRDN icon
25
Viridian Therapeutics
VRDN
$2.09B
$6.5M 1.25%
500,000
-835,000
-63% -$11.6M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Great Point Partners held 42 positions worth $522M, down 19% from $642M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Great Point Partners withdrew a net $60.3M in Q2 2024, closing 9 positions and reducing 8 holdings. Its most notable exit was Alpine Immune Sciences Inc, an estimated $44.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Great Point Partners opened a new position in KalVista Pharmaceuticals worth $15.8M.

  • Great Point Partners's largest Q2 2024 buy was KalVista Pharmaceuticals: 1,338,568 shares worth $15.8M.
  • Great Point Partners added most to Cytokinetics in Q2 2024, an estimated $16.4M increase.
  • Great Point Partners's biggest Q2 2024 reduction was AnaptysBio, cutting an estimated $22.2M.
  • Great Point Partners fully exited Alpine Immune Sciences Inc in Q2 2024, selling an estimated $44.7M.
  • Great Point Partners's ten largest holdings make up 58% of its $522M portfolio in Q2 2024.
  • Great Point Partners opened 7 new positions and closed 9 in Q2 2024.
  • Great Point Partners's portfolio value fell 19% quarter-over-quarter to $522M.

Based on Great Point Partners's 13F filing for Q2 2024, filed 14 Aug 2024.